Abstract Library

#4380 Cell-free DNA concentration correlates with copy number variant (CNV)-count, describes tumour progression and nuclear instability in GEP-NETs

Introduction: Cell-free DNA (cfDNA) levels depend on various factors related to the shedding of cells and might provide valuable information on tumour state and treatment success. In a genomic profiling pilot study conducted as part of the COMPOSE Phase III multicentre open-labelled clinical trial we assessed multiple factors and their impact on cfDNA levels in 14 GEP-NET patients.

Conference:

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Capdevila J, Smutna V, Weckwerth W, Erdoe M,

Keywords: CNV, cfDNA, liquid biopsy, quantitative marker, cfDNA concentration, longitudinal, GEP-NET, genomic profiling,

#3480 Is addition of NETest to clinical parameters valuable in the prognostication of patients with Small Intestinal Neuroendocrine Tumors (SI-NET)?

Introduction: A previously established nomogram based on clinical parameters was associated with disease specific survival (DSS) in patients with SI-NET, yet it underestimated DSS. (1,2)

Conference:

Presenting Author: Levy S

Authors: Levy S, van Treijen M, Tesselaar M, Valk G,

Keywords: SI-NET, Nomogram, NETest, DSS, PFS,

#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hernando-Cubero J

Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,

Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,

#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients

Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Genus T

Authors: Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B,

Keywords: Neuroendocrine cancer, second primary, metachronous,

#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)

Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Ardill J

Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,

Keywords: MGC,